{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:46:45Z","timestamp":1788896805642,"version":"build-2803163510"},"reference-count":13,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":2137,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2006,3]]},"abstract":"\n Study Objective<\/jats:bold>\n . To evaluate the outcomes in patients with bacteremia and\/or infective endocarditis who were treated with daptomycin.\n <\/jats:p>\n \n Design<\/jats:bold>\n . Retrospective chart review.\n <\/jats:p>\n \n Setting<\/jats:bold>\n . A university\u2010affiliated medical center in Chicago, Illinois, and a regional hospital in Fountain Valley, California.\n <\/jats:p>\n \n Patients<\/jats:bold>\n . Thirty\u2010one inpatients treated with daptomycin for bacteremia and\/or infective endocarditis.\n <\/jats:p>\n \n Measurements and Main Results<\/jats:bold>\n . Patients were given daptomycin 4\u20136 mg\/kg intravenously every 24\u201348 hours based on the practitioner's discretion and depending on the patient's clinical condition and presence of comorbidities. Primary end points were resolution of signs and symptoms of infection and discharge from the hospital. Methicillin\u2010resistant\n Staphylococcus aureus<\/jats:italic>\n ([MRSA] 11 patients) and vancomycin\u2010resistant entercocci ([VRE] 11 patients) were the most common pathogens, whereas 7 patients had methicillin\u2010sensitive\n S. aureus<\/jats:italic>\n infection and 1 patient had coagulase\u2010negative\n Staphylococcus<\/jats:italic>\n infection. One patient with endocarditis had a negative culture result. Overall, 24 (77%) of the 31 patients achieved clinical resolution and were discharged, including all patients infected with MRSA; 7 patients died, 6 of whom had VRE infection. Duration of treatment for infective endocarditis lasted longer (typically 22\u201343 days) than that for bacteremia only (\u2264 14 days), and no patients discontinued daptomycin because of adverse events.\n <\/jats:p>\n \n Conclusion<\/jats:bold>\n . In these patients, daptomycin was safe and well tolerated even for extended durations of treatment. Daptomycin may provide an effective option for treating drug\u2010resistant gram\u2010positive bloodstream infections and endocarditis.\n <\/jats:p>","DOI":"10.1592\/phco.26.3.347","type":"journal-article","created":{"date-parts":[[2006,2,27]],"date-time":"2006-02-27T08:49:56Z","timestamp":1141030196000},"page":"347-352","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Daptomycin for the Treatment of Gram\u2010Positive Bacteremia and Infective Endocarditis: A Retrospective Case Series of 31 Patients"],"prefix":"10.1002","volume":"26","author":[{"given":"John A.","family":"Segreti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W.","family":"Crank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Finney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000119424.31648.1E"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/520192"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2004.10.001"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/345476"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/313440"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/314712"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.6.2398-2402.2004"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-4399(02)80007-1"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/420818"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.8.2682-2684.2003"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/313753"},{"key":"e_1_2_1_13_2","volume-title":"Cubicin (daptomycin for injection) product information","author":"Cubist Pharmaceuticals","year":"2003"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.2948-2953.2000"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.26.3.347","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.26.3.347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:25:31Z","timestamp":1761067531000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.26.3.347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1592\/phco.26.3.347"],"URL":"https:\/\/doi.org\/10.1592\/phco.26.3.347","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}